About Us

G. Paul Bosse III

Chief Executive Officer & Founder

G. Paul Bosse III has served as the President and Chief Executive Officer of Charleston Laboratories, Inc. since 2007. Mr. Bosse is the inventor of Charleston’s novel product concepts, drug delivery platforms, and patent filings, as well as the Company’s original founding member.

With 15 years of sales, marketing, and executive management experience in the pharmaceutical industry, and as a former founder of a small, privately held pharmaceutical company, Mr. Bosse brings a wealth of experience managing strategic partnerships to Charleston.

A natural leader with a distinctive energy, Mr. Bosse’s determination and drive won’t allow him to simply meet goals—but rather exceed expectations and milestones in everything he does. It’s this mindset that makes Mr. Bosse ideally suited to leading Charleston forward as an ethically responsible pharmaceutical company, committed to change in the face of the current opioid crisis.

Key Accomplishments

  • Primary inventor of Charleston’s novel product concepts, drug delivery platforms, and patent filings
  • Assembly of top-tier executive management team, leading company through all capital financings and milestones
  • Recognized by major financial institutions for his executive leadership, strategic prowess, and entrepreneurship
  • BA in Sociology from Samford University

Ryan T. Baker

Senior Executive Vice President,
Chief Strategy Officer & Founder

Ryan T. Baker serves as the Senior Executive Vice President and Chief Strategy Officer of Charleston Laboratories, Inc. and is also the company’s original co-founding member. As a previous co-founder of a start-up specialty pharmaceutical company, Mr. Baker is well versed in the industry and contributes to Charleston’s strategic business planning, fundraising, relationship management and more.

Key Accomplishments

  • 11 years working in Wealth Management industry at Merrill Lynch and Morgan Stanley respectively
  • Finance Degree from University of Alabama, with specialization in Corporate Investment Management

Joseph P. Hazelton

Executive Vice President,
Chief Operating Officer

Joseph P. Hazelton serves as the Executive Vice President, and Chief Operating Officer of Charleston Laboratories, Inc. Mr. Hazelton initially joined Charleston to lead the company’s transition to the commercial stage of the novel fixed-dose combination pain product, CL-108. After two years, he was promoted to Chief Operating Officer so the company could benefit from his leadership and vast experience. Mr. Hazelton had previously spent over 15 years at Novartis Pharmaceuticals Corporation, in roles of increasing responsibility within the areas of managed markets/market access, retail and specialty pharmaceuticals, pricing, sales, and marketing.

Key Accomplishments

  • Executive member of US Managed Markets and Brand leadership teams
  • Spent over 10 years in managed markets with direct responsibility for development and execution of the market access and pricing functions
  • Built and led sales and account management teams to profitable sales and access in multiple therapeutic areas for blockbuster medications, such as Diovan®, Lamisil®, and Gilenya®
  • BA from the College of the Holy Cross in Worcester, MA

Bernard P. Schachtel, MD

Chief Scientific Officer & Founder

Dr. Bernard P. Schachtel helped to found Charleston Laboratories, Inc. in 2007 and currently serves as its Chief Scientific Officer and Member of the Scientific Advisory Board. Dr. Schachtel serves as the President of Schachtel Research Company (SRC), has over 30 years’ experience in analgesic research, and has served as Consultant to the Center for Drug Evaluation and Research at the U.S. Food and Drug Administration.

Throughout his career, Dr. Schachtel has held academic appointments at McGill University, the University of Pittsburgh, and Yale University, where he is a Lecturer in Epidemiology and Public Health. After residency and a fellowship at the National Institutes of Health, he was a Robert Wood Johnson Clinical Scholar in the Departments of Medicine and Epidemiology and Public Health at the Yale University School of Medicine. Dr. Schachtel was also a leading developer of the pain measurement scales, which assess and compare the efficacy of analgesics.

Key Accomplishments

  • Robert Wood Johnson Clinical Scholar in the Departments of Medicine and Epidemiology and Public Health at the Yale University School of Medicine
  • Research fellowship at the National Institutes of Health
  • BA from Yale College; MD from Columbia University, College of Physicians and Surgeons
  • Graduated Valedictorian Cum Laude from Collegiate School in New York City

George A. Scott, Jr.,
JD, MBA

Chief Legal Officer & General Counsel

George A. Scott joined Charleston Laboratories in January 2016 after serving as outside counsel for the company since 2014.  Mr. Scott serves as the company’s Chief Legal Officer and General Counsel. Mr. Scott manages and oversees all of the legal affairs for the company and its affiliates, including all issues related to partnerships and alliances, mergers and acquisitions, labor and employment, corporate governance, compliance, litigation, and management of risk for Charleston. Prior to joining the company, Mr. Scott spent several years with large global law firms, most recently with Greenberg Traurig. Mr. Scott brings over a decade of legal experience representing public and private companies, including numerous emerging pharmaceutical and life-science companies. Prior to his legal career, he worked in investment banking for one of the largest investment banks in the world. Mr. Scott holds a BS from Syracuse University, an MBA from Wagner College, and a JD from Charlotte School of Law.

Key Accomplishments

  • BS in Political Philosophy from Syracuse University
  • MBA in Business Management from Wagner College
  • JD from Charlotte School of Law

Thomas Smith, MD

Chief Medical Officer

Dr. Thomas Smith joined Charleston Laboratories as Chief Medical Officer in late December 2016. As CMO, Dr. Smith has executive responsibility for advancing research, development, and life cycle initiatives for all pipeline products. Dr. Smith also collaborates with the executive team in setting global strategy, and works closely with medical and regulatory agencies. With more than 25 years of diverse experience in healthcare, Dr. Smith has been instrumental in helping bring to market effective and safe medications to serve millions of patients around the globe.

Key Accomplishments

  • BS from Purdue University
  • MD from the Indiana University School of Medicine
  • 12 years as private practitioner and clinical investigator
  • Several executive leadership roles in major pharmaceutical corporations including Abbott Laboratories, Genzyme, Teva, and Mallinckrodt Pharmaceuticals

Terrence Terifay

Chief Commercial Officer

Terrence Terifay serves as Chief Commercial Officer of Charleston Laboratories, Inc. since December 2016. Mr. Terifay has executive responsibility and directly manages all commercialization efforts, including establishing the US & Global commercial strategy, global market access, and building the US commercial infrastructure to support the robust pipeline of fixed-dose combination products in the CNS, Respiratory and Pain marketplaces. Mr. Terifay has more than 20 years of diverse executive experience in corporate strategy and build-out, general management, commercial operations, marketing, sales, market access, customer insights and analytics, and organizational operations.

Key Accomplishments

  • Previous Senior Vice President, Chief Commercial Officer at Optinose
  • Executive roles with Mallinckrodt Pharmaceuticals, Covidien, and Cephalon
  • Completed advanced leadership and management coursework from Washington University, St. Louis
  • BS in Finance, and Risk Management and Insurance from La Salle University, Philadelphia

Mark A. Mannebach,
PhD, RPh

Vice President of Global Regulatory
Affairs & Quality Assurance

Dr. Mark A. Mannebach serves as the Vice President of Global Regulatory Affairs and Quality Assurance at Charleston Laboratories, Inc. As Vice President, Dr. Mannebach has the responsibilities of working with the executive team to develop and maintain the global regulatory strategy, managing all regulatory submissions and renewals, and developing the technical requirements of supply and quality agreement contracts. Dr. Mannebach has more than 30 years of experience in the pharmaceutical industry working in leadership roles including at Parke-Davis/Warner-Lambert, Pharmacia, Baxter, and Pfizer.

Key Accomplishments

  • VP of Global Regulatory Affairs at Mallinckrodt
  • Worked with the Division of Anesthesia, Analgesia and Addiction Products (DAAAP) on NDAs
  • Worked on approved pain products including Exalgo®, Pennsaid® (both 1.5% & 2% topical solutions), Xartemis® XR and Ofirmev®
  • BS in Pharmacy from Wayne State University
  • MS in Chemical Engineering from University of Detroit
  • PhD in Pharmacy Administration from University of Michigan

John F. Ameling

Vice President of Regulatory Affairs

John F. Ameling serves as Vice President of Regulatory Affairs at Charleston Laboratories, Inc. With over 32 years of experience working in regulatory affairs, Mr. Ameling has successfully executed 5 NDAs and submitted over 40 INDs to the FDA. Mr. Ameling has coordinated over 125 meetings with the FDA, presented to FDA Advisory Committees, been an “expert witness” in several lawsuits and testified before the US Congress. As Charleston’s Vice President of Regulatory Affairs, Mr. Ameling’s duties include leading all communications with the FDA, directing regulatory strategy for the company’s novel pipeline of products, and managing contract manufacturing.

Key Accomplishments

  • Founder and President of Regulatory Affairs Partners, LLC
  • Won an Outstanding Achievement Award from the Regulatory Affairs Professional Society for serving as Chairman of the Education Committee
  • BS in Psychology from University of Cincinnati

William J. Kozarek, PhD

Vice President of Product Development

Dr. William J. Kozarek serves as Vice President of Product Development at Charleston Laboratories, Inc. He has 29 years of industrial experience and nine years of consulting to the pharmaceutical industry. Dr. Kozarek has extensive experience in Rx and OTC drugs and has played key roles in the Rx to OTC switch of Prilosec®, Aleve® and Femstat®.

Key Accomplishments

  • President of Kozarek Regulatory Consulting, Inc.
  • Adjunct Professor at the University of Cincinnati, School of Pharmacy
  • PhD in Analytical Chemistry from University of Arizona